4 Top Stocks With Debt-to-Equity of 1-3 and ROE Above 15 to Watch for Future Multibagger Potential: M&M, Torrent Pharma, Narayana Health and Nuvama

Stocks with debt-to-equity of 1-3 and ROE above 15 to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. M&M, Torrent Pharma, Narayana Health and Nuvama meet that test, with market caps from Rs 31,681 crore to Rs 3.48 lakh crore and M&M offering the strongest latest-quarter profit growth at 37.04%. Each of these companies has a debt-to-equity ratio between 1 and 3 and a return on equity of at least 15 per cent, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a debt-to-equity ratio between 1 and 3 and a return on equity of at least 15 per cent, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. The companies here range from midcaps to largecaps in size. Investors screening stocks with debt-to-equity of 1-3 and ROE above 15 usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 20 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Stocks With Debt-to-Equity of 1-3 and ROE Above 15 and Why Do They Attract Multibagger Interest?

Stocks with debt-to-equity of 1-3 and ROE above 15 are shares of companies that use borrowing and still earn healthy returns. The four here cover vehicles, pharmaceuticals, hospitals and wealth management.

Borrowing works when returns stay above its cost. For stocks with debt-to-equity of 1-3 and ROE above 15, strong returns and rising profit point that way. Whichever way you read stocks with debt-to-equity of 1-3 and ROE above 15, the common thread is rising profit backed by complete financial data. With stocks with debt-to-equity of 1-3 and ROE above 15, comparing valuation, growth and balance sheet strength together works better than relying on one number. Every company in the table below passed a rising-profit check, and the figures for stocks with debt-to-equity of 1-3 and ROE above 15 are complete. Read each company's latest results and exchange filings before acting on stocks with debt-to-equity of 1-3 and ROE above 15.

Stocks With Debt-to-Equity of 1-3 and ROE Above 15 at a Glance: Price, Market Cap, PE, ROE and Price to Book

Prices are closing prices as of 20 October 2026. M&M has the lowest PE of the group at 17.19, while Torrent Pharma posts the highest return on equity at 25.49%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Price to Book	52-Week Range (Rs)
Mahindra & Mahindra	2,907	3,48,064	17.19	23.82	18.37%	3.74	2,744.30 to 3,839.90
Torrent Pharmaceuticals	4,558.70	1,75,196	81.26	36.42	25.49%	20.83	3,480.60 to 5,250.00
Narayana Hrudayalaya	1,740.90	35,224	43.13	60.75	17.76%	7.76	1,589.00 to 2,093.30
Nuvama Wealth Management	1,683.80	31,681	29.28	33.31	25.26%	7.72	1,096.90 to 2,066.00

M&M: 26.58% Profit CAGR Since FY22

Mahindra & Mahindra is one of the largest SUV makers in India and the country's largest tractor maker, with financial services and electric vehicles in its portfolio. It reported FY26 revenue of Rs 2,02,084.34 crore, up 25.21% year on year, and net profit of Rs 18,621.71 crore, up 32.32%. Net profit has compounded at 26.58% a year since FY22, while revenue has grown 22.04% a year. Operating margin was 21.19% in FY26.

In the June 2026 quarter, revenue rose 27.47% to Rs 59,203.60 crore and net profit grew 37.04% to Rs 5,997.56 crore. The share price has gained 220.52% over five years. Domestic institutions raised their holding from 29.59% in June 2025 to 32.65% in June 2026. The stock trades at a PE of 17.19 against an industry PE of 23.82, below the sector average, with a return on equity of 18.37%.

Torrent Pharma: 28.79% Profit CAGR Since FY22

Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.

The stock trades at a PE of 81.26 against an industry PE of 36.42, with a return on equity of 25.49%. In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026.

Narayana Health: 24.06% Profit CAGR Since FY22

Narayana Health runs a network of multi-speciality hospitals, with a strong cardiac care franchise and a presence in India and the Cayman Islands. It reported FY26 revenue of Rs 7,996.25 crore, up 43.43% year on year, and net profit of Rs 810.46 crore, up 2.61%. Net profit has compounded at 24.06% a year since FY22, while revenue has grown 20.95% a year. Operating margin was 21.25% in FY26.

In the June 2026 quarter, revenue rose 77.60% to Rs 2,719.11 crore and net profit grew 5.37% to Rs 207.27 crore. The share price has gained 225.59% over five years. Domestic institutions raised their holding from 7.76% in September 2025 to 10.68% in September 2026. The stock trades at a PE of 43.13 against an industry PE of 60.75, below the sector average, with a return on equity of 17.76%.

Nuvama: Return on Equity of 25.26%

Nuvama Wealth Management offers wealth management, asset services and capital markets services to affluent clients and institutions. It reported FY26 revenue of Rs 4,649.65 crore, up 11.52% year on year, and net profit of Rs 1,040.26 crore, up 5.60%. Revenue has compounded at 27.07% a year since FY22. Operating margin was 53.05% in FY26.

The stock trades at a PE of 29.28 against an industry PE of 33.31, below the sector average, with a return on equity of 25.26%. The dividend yield is 1.60%. In the June 2026 quarter, revenue rose 22.88% to Rs 1,381.96 crore and net profit grew 15.83% to Rs 305.64 crore. The share price is up 19.71% over the past year. Domestic institutions raised their holding from 6.37% in June 2025 to 8.49% in June 2026.

Stocks With Debt-to-Equity of 1-3 and ROE Above 15: Financial Comparison on Growth and Margins

The table compares scale and growth across these stocks with debt-to-equity of 1-3 and ROE above 15. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	4-Year Net Profit CAGR	Operating Margin (Latest Quarter)
M&M	2,02,084.34	18,621.71	25.21%	22.04%	26.58%	20.77%
Torrent Pharma	13,886.15	2,138.18	20.34%	12.38%	28.79%	33.73%
Narayana Health	7,996.25	810.46	43.43%	20.95%	24.06%	18.75%
Nuvama	4,649.65	1,040.26	11.52%	27.07%	4.96%	53.22%

Check the Univest Screener for live data on these stocks with debt-to-equity of 1-3 and ROE above 15

Institutional Holding in M&M, Torrent Pharma, Narayana Health and Nuvama

Institutional holding shows who is backing these stocks with debt-to-equity of 1-3 and ROE above 15 alongside the promoter. The table uses the latest reported quarter for each. M&M has the deepest institutional backing, with FII and DII together holding 67.54% as of June 2026. Domestic institutions increased their holding over the past year in M&M (from 29.59% to 32.65%), Torrent Pharma (from 9.28% to 12.87%), Narayana Health (from 7.76% to 10.68%) and Nuvama (from 6.37% to 8.49%).

Stock	Promoter	FII	DII	Public	Quarter
M&M	18.45%	34.89%	32.65%	14.01%	June 2026
Torrent Pharma	60.78%	17.97%	12.87%	8.38%	July 2026
Narayana Health	63.27%	9.01%	10.68%	17.04%	September 2026
Nuvama	53.98%	19.00%	8.49%	18.53%	June 2026

Risks to Weigh in Stocks With Debt-to-Equity of 1-3 and ROE Above 15

Being careful with stocks with debt-to-equity of 1-3 and ROE above 15 means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings need to keep growing to support the price.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Stocks With Debt-to-Equity of 1-3 and ROE Above 15

Picking from stocks with debt-to-equity of 1-3 and ROE above 15 comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (23.82 to 60.75) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track M&M, Torrent Pharma, Narayana Health and Nuvama live prices.

Conclusion

Among stocks with debt-to-equity of 1-3 and ROE above 15, M&M stands out for the strongest latest-quarter profit growth at 37.04%, Torrent Pharma for the highest return on equity at 25.49%, Narayana Health for the biggest five-year price gain at 225.59% and Nuvama for 11.52% revenue growth in FY26. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing stocks with debt-to-equity of 1-3 and ROE above 15 should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Stocks With Debt-to-Equity of 1-3 and ROE Above 15 to Watch

Which are the best stocks with debt-to-equity of 1-3 and ROE above 15 to watch for multibagger potential?

Ans. M&M, Torrent Pharma, Narayana Health and Nuvama are the 4 names this list highlights, with market caps of Rs 3,48,064 crore, Rs 1,75,196 crore, Rs 35,224 crore and Rs 31,681 crore respectively. M&M is notable for the strongest latest-quarter profit growth at 37.04%. Torrent Pharma stands out for the highest return on equity at 25.49%. Narayana Health offers the biggest five-year price gain at 225.59%. Nuvama brings 11.52% revenue growth in FY26. These are watchlist names for stocks with debt-to-equity of 1-3 and ROE above 15, not recommendations, so match each one to your own risk profile and time horizon.

Is Torrent Pharma a good stock for long-term investors?

Ans. Torrent Pharma has a return on equity of 25.49%, a PE of 81.26 against an industry PE of 36.42 and a market cap of Rs 1,75,196 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in stocks with debt-to-equity of 1-3 and ROE above 15 depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can M&M become a multibagger from here?

Ans. M&M has already gained 220.52% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in stocks with debt-to-equity of 1-3 and ROE above 15 requires earnings to keep growing faster than the market for several years. Net profit has compounded at 26.58% a year since FY22, and FY26 revenue rose 25.21%. At a PE of 17.19 against an industry PE of 23.82, valuation should be checked against that growth before investing.

What is the market cap of M&M, Torrent Pharma, Narayana Health and Nuvama?

Ans. As of 20 October 2026, M&M has a market cap of Rs 3,48,064 crore, Torrent Pharma has a market cap of Rs 1,75,196 crore, Narayana Health has a market cap of Rs 35,224 crore and Nuvama has a market cap of Rs 31,681 crore. M&M is the largest of the group. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on stocks with debt-to-equity of 1-3 and ROE above 15.

What are the risks of investing in stocks with debt-to-equity of 1-3 and ROE above 15?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings growth needs to hold up.

Why is Torrent Pharma trading at a PE of 81.26?

Ans. Torrent Pharma's PE of 81.26 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in stocks with debt-to-equity of 1-3 and ROE above 15 who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in M&M, Torrent Pharma, Narayana Health and Nuvama?

Ans. As of the latest reported quarter, FII and DII together hold 67.54% of M&M (34.89% and 32.65%), 30.84% of Torrent Pharma (17.97% and 12.87%), 19.69% of Narayana Health (9.01% and 10.68%) and 27.49% of Nuvama (19.00% and 8.49%). Rising institutional holding is a useful signal in stocks with debt-to-equity of 1-3 and ROE above 15, though it should be read with earnings trends rather than on its own.